Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 3, 2010, Pages 811-821

  Moyer, Ann M ^a   Sun, Zhifu ^b   Batzler, Anthony J ^c   Li, Ang ^a   Schaid, Daniel J ^c   Yang, Ping ^b   Weinshilboum, Richard M ^a  

^a Division of Clinical Pharmacology   (United States)

^b Department of Health Sciences Research ^*  (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; CISPLATIN; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE A5; GLUTATHIONE TRANSFERASE M4; GLUTATHIONE TRANSFERASE T1; PROTEIN ABCC4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOTOXICITY; DNA DETERMINATION; FEMALE; GENE OVEREXPRESSION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; IC 50; LUNG CANCER; LYMPHOBLASTOID CELL LINE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE DOSAGE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HUMANS; ISOENZYMES; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; SIGNAL TRANSDUCTION;

EID: 77949674534     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0871     Document Type: Article

References (48)

1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573-84.
2. Reed E. Cisplatin, Carboplatin, and Oxaliplatin. In: Chabner B, editor. Cancer Chemotherapy and Biotherapy.: Lippincott Williams & Wilkins; 2006, p. 332-43.
3. Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode. Nature 1965;205:698-9.
4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
5. Eastman A. Characterization of the adducts produced in DNA by cisdiamminedichloroplatinum( II) and cis-dichloro(ethylenediamine)platinum( II). Biochemistry 1983;22:3927-33.
6. Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, Lohman PH, Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum( II) with DNA: formation, identification, and quantitation. Biochemistry 1985;24:707-13.
7. Lindauer E, Holler E. Cellular distribution and cellular reactivity of platinum (II) complexes. Biochem Pharmacol 1996;52:7-14.
8. Lippard SJ. Chemistry and molecular biology of platinum anticancer drugs. Pure & Appl. Chem. 1987;59:731-42.
9. Harder HC, Rosenberg B. Inhibitory effects of anti-tumor platinum compounds on DNA, RNA and protein syntheses in mammalian cells in vitro. Int J Cancer 1970;6:207-16.
10. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-20.
11. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33:9-23.
12. Wang G, Reed E, Li QQ. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncol Rep 2004;12:955-65.
13. Yang P, Ebbert JO, Sun Z, Weinshilboum RM. Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol 2006;24:1761-9.
14. Devesa SS, Grauman DJ, Blot WJ, Pennello GA, Hoover RN, Fraumeni JF, Jr. Atlas of cancer mortality in the United States, 1950-94. Washington (DC): US Govt Print Off; 1999.
15. Yang P, Yokomizo A, Tazelaar HD, et al. Genetic determinants of lung cancer short-term survival: the role of glutathione-related genes. Lung Cancer 2002;35:221-9.
16. Sun Z, Aubry MC, Deschamps C, et al. Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases. J Thorac Cardiovasc Surg 2006;131:1014-20.
17. Visbal AL, Williams BA, Nichols FC III, et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 2004;78: 209-15, discussion 215.
18. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005;128:452-62.
19. Wielinga PR, Reid G, Challa EE, et al. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol 2002;62:1321-31.
20. Moyer AM, Salavaggione OE, Hebbring SJ, et al. Glutathione Stransferase T1 and M1: gene sequence variation and functional genomics. Clin Cancer Res 2007;13:7207-16.
21. Moyer AM, Salavaggione OE, Wu TY, et al. Glutathione S-transferase P1: gene sequence variation and functional genomic studies. Cancer Res 2008;68:4791-801.
22. Mukherjee B, Salavaggione OE, Pelleymounter LL, et al. Glutathione S-transferase ω 1 and ω 2 pharmacogenomics. Drug Metab Dispos 2006;34:1237-46.
23. Hartl D, Clark AG. Chapter 3. Organization of genetic variation. Principles of Population Genetics. Sunderland (MA): Sinauer Associates, Inc.; 2000, p. 95-107.
24. Hendrick P. Genetics of Populations. Sudbury (MA): Jones and Bartlett Publishing; 2000, p. 396-405.
25. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
26. Li L, Fridley B, Kalari K, et al. Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res 2008;68:7050-8.
27. Wang L, Sullivan W, Toft D, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. Pharmacogenetics 2003;13:555-64.
28. Salavaggione OE, Wang L, Wiepert M, Yee VC, Weinshilboum RM. Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics 2005;15:801-15.
29. Cheung VG, Spielman RS, Ewens KG, Weber TM, Morley M, Burdick JT. Mapping determinants of human gene expression by regional and genome-wide association. Nature 2005;437: 1365-9.
30. Eastman A, Schulte N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry 1988; 27:4730-4.
31. Ishikawa T, Ali-Osman F. Glutathione-associated cis- diamminedichloroplatinum( II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 1993;268: 20116-25.
32. Loh SY, Mistry P, Kelland LR, Abel G, Harrap KR. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br J Cancer 1992;66:1109-15.
33. Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res 1992; 52:6885-9.
34. Eastman A. Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes. Chem Biol Interact 1987;61:241-8.
35. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A 1992;89:3070-4.
36. Hann CL, Rudin CM. Management of small-cell lung cancer: incremental changes but hope for the future. Oncology (Williston Park) 2008;22:1486-92.
37. Sanborn RE. Cisplatin versus carboplatin in NSCLC: Is there one "best" answer? Curr Treat Options Oncol 2008;9:326-42.
38. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 2002;13:595-603.
39. Medeiros R, Pereira D, Afonso N, et al. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione Stransferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 2003;8:156-61.
40. Watson MB, Lind MJ, Smith L, Drew PJ, Cawkwell L. Expression microarray analysis reveals genes associated with in vitro resistance to cisplatin in a cell line model. Acta Oncol 2007;46:651-8.
41. Liloglou T, Walters M, Maloney P, Youngson J, Field JK. A T2517C polymorphism in the GSTM4 gene is associated with risk of developing lung cancer. Lung Cancer 2002;37:143-6.
42. Morel F, Rauch C, Coles B, Le Ferrec E, Guillouzo A. The human glutathione transferase α locus: genomic organization of the gene cluster and functional characterization of the genetic polymorphism in the hGSTA1 promoter. Pharmacogenetics 2002;12: 277-86.
43. Muller M, Meijer C, Zaman GJ, et al. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci U S A 1994;91:13033-7.
44. Zaman GJ, Lankelma J, van Tellingen O, et al. Role of glutathione in the export of compounds from cells by the multidrug-resistanceassociated protein. Proc Natl Acad Sci U S A 1995;92:7690-4.
45. Kool M, de Haas M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997;57:3537-47.
46. Savaraj N, Wu C, Wangpaichitr M, et al. Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine. Int J Oncol 2003; 23:173-9.
47. Wakamatsu T, Nakahashi Y, Hachimine D, Seki T, Okazaki K. The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int J Oncol 2007;31: 1465-72.
48. http://www.cancer.org/docroot/CRI/content/CRI-2-4-3x-How-Is-Small-Cell- Lung-Cancer-Staged.asp